CSL has announced the listing of Andembry (garadacimab) on the Pharmaceutical Benefits Scheme (PBS) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in eligible patients.
HAE is a rare, chronic, and potentially life-threatening genetic disorder characterised by recurrent and unpredictable attacks of swelling that are often painful and can affect multiple parts of the body, including the abdomen, larynx, face and extremities.
The drug is a once-monthly treatment delivered by subcutaneous self-injection that targets activated factor XII (FXIIa), a plasma protein that initiates the cascade of events leading to attacks of swelling in people living with HAE.
"Andembry represents Australian innovation at its best, having been discovered in our Melbourne research laboratories and manufactured in Victoria," said Danielle Dowell, executive director and GM, CSL Australia and New Zealand.
"We welcome its PBS listing and remain committed to supporting the HAE community and partnering with clinicians, government and patient organisations to enable timely access to innovative therapies."
Meanwhile, people with living with heart failure with reduced ejection fraction (HFrEF) can now access a PBS-reimbursed treatment option aligned with clinical guidelines, following the PBS restriction change for eplerenone (Inspra and other brands).
The change removes the requirement for eplerenone treatment to commence in hospital within 14 days of an acute myocardial infarction, with initiation now also possible outside of a hospital setting under the care of a GP.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Apr 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Apr 26
